Trial Profile
An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs ABSK 091 (Primary) ; Adavosertib (Primary) ; Danvatirsen (Primary) ; Durvalumab (Primary) ; Olaparib (Primary) ; Selumetinib (Primary) ; Vistusertib (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Adverse reactions; Biomarker
- Acronyms BISCAY
- Sponsors AstraZeneca
- 08 Dec 2023 Planned End Date changed from 29 Sep 2023 to 28 Jun 2024.
- 16 Mar 2023 Planned End Date changed from 31 Mar 2023 to 29 Sep 2023.
- 17 Oct 2022 Planned End Date changed from 12 Sep 2022 to 31 Mar 2023.